News and Trends 12 Jul 2022
Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa
Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […]